Seagen Inc. (SGEN): Price and Financial Metrics

Seagen Inc. (SGEN): $228.74

0.16 (-0.07%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add SGEN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#103 of 344

in industry

SGEN Price/Volume Stats

Current price $228.74 52-week high $228.96
Prev. close $228.90 52-week low $123.77
Day low $228.74 Volume 20,075,400
Day high $228.96 Avg. volume 1,478,439
50-day MA $215.13 Dividend yield N/A
200-day MA $202.50 Market Cap 42.93B

SGEN Stock Price Chart Interactive Chart >


Seagen Inc. (SGEN) Company Bio


Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. (Source:Wikipedia)


SGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

SGEN Latest Social Stream


Loading social stream, please wait...

View Full SGEN Social Stream

Latest SGEN News From Around the Web

Below are the latest news stories about SEAGEN INC that investors may wish to consider to help them evaluate SGEN as an investment opportunity.

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-con

Yahoo | December 15, 2023

3 Stocks That Are About to Get Absolutely Crushed

These are a few different companies that are experiencing difficult times and that are expected to keep falling.

Noah Bolton on InvestorPlace | December 14, 2023

3 Sleepy Stocks Ready to Wake up in 2024

Strong projected earnings growth makes these three stocks strong candidates for exceptional growth in 2024.

Chris Markoch on InvestorPlace | December 13, 2023

Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House

The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.

Yahoo | December 13, 2023

We're Interested To See How Seagen (NASDAQ:SGEN) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | December 12, 2023

Read More 'SGEN' Stories Here

SGEN Price Returns

1-mo N/A
3-mo N/A
6-mo 6.41%
1-year 11.36%
3-year 57.21%
5-year 230.64%
YTD N/A
2023 0.00%
2022 -16.88%
2021 -11.73%
2020 53.28%
2019 101.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!